Tyrosine Kinase Stocks List

Recent Signals

Date Stock Signal Type
2021-02-24 BBIO 50 DMA Support Bullish
2021-02-24 BPMC 20 DMA Resistance Bearish
2021-02-24 EXEL NR7 Range Contraction
2021-02-24 EXEL Bollinger Band Squeeze Range Contraction
2021-02-24 EXEL Crossed Above 200 DMA Bullish
2021-02-24 EXEL Crossed Above 20 DMA Bullish
2021-02-24 EYPT Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-02-24 KALA NR7 Range Contraction
2021-02-24 KALA 200 DMA Resistance Bearish
2021-02-24 KALA 20 DMA Support Bullish
2021-02-24 KIN Fell Below 50 DMA Bearish
2021-02-24 KRON 20 DMA Support Bullish
2021-02-24 NRIX 20 DMA Resistance Bearish
2021-02-24 NRIX 50 DMA Resistance Bearish
2021-02-24 NRIX Shooting Star Candlestick Bearish
2021-02-24 NRIX Bollinger Band Squeeze Range Contraction
2021-02-24 NRIX Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-02-24 PBYI MACD Bearish Centerline Cross Bearish
2021-02-24 PBYI Stochastic Buy Signal Bullish
2021-02-24 PBYI Bullish Engulfing Bullish
2021-02-24 RIGL Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-02-24 RIGL 1,2,3 Pullback Bullish Bullish Swing Setup
2021-02-24 RIGL Crossed Above 20 DMA Bullish

Recent News for Tyrosine Kinase Stocks

Date Stock Title
Feb 25 PBYI Puma Biotechnology EPS misses by $0.05, misses on revenue
Feb 25 PBYI Puma Biotechnology and Pierre Fabre amend NERLYNX license agreement
Feb 25 PBYI Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
Feb 25 PBYI Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Feb 25 EXEL Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in March
Feb 25 KIN Kindred Biosciences Submits Efficacy Data For KIND-030 As Prophylactic Option In US
Feb 25 EXEL Exelixis' Cabozantinib Gets Breakthrough Therapy Status In Differentiated Thyroid Cancer
Feb 25 EXEL Exelixis' CABOMETYX wins FDA's breakthrough therapy status
Feb 25 KIN Kindred submits efficacy data to support KIND-030 prophylactic indication approval
Feb 25 KIN Kindred Biosciences Announces Submission of Parvovirus Monoclonal Antibody Data for Prophylactic Indication
Feb 25 KRON Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
Feb 25 EXEL Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Feb 25 BBIO BridgeBio Pharma EPS misses by $0.16, misses on revenue
Feb 25 BBIO BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update
Feb 25 KALA Kala Pharmaceuticals EPS misses by $0.09, misses on revenue
Feb 25 EYPT EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
Feb 25 KALA Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Feb 25 KIN Is Kindred Biosciences (NASDAQ:KIN) Using Too Much Debt?
Feb 24 PBYI Puma Biotechnology Q4 2020 Earnings Preview
Feb 24 BBIO BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society’s 2021 Annual Meeting
Related Industries: Biotechnology Other